Bruce Clurman

Bruce Clurman, MD, PhD, serves as Executive Vice President, Chief Scientific Officer, and Deputy Director of Fred Hutchinson Cancer Center. He holds the Rosput Reynolds Endowed Chair and is a Professor in both the Translational Science and Therapeutics Division and Human Biology Division at Fred Hutch, with additional appointments as Professor in the University of Washington Department of Medicine and Adjunct Professor in Pathology.

His educational background includes:

• BA in Philosophy, University of Virginia (1981)
• PhD in Viral Oncology, Cornell University Graduate School of Medical Sciences (1988)
• MD, Cornell University Medical College (1989)
• Residency at Brigham and Women’s Hospital, Boston
• Fellowship in Medical Oncology/Molecular Medicine at Fred Hutch and UW

Dr. Clurman's research centers on cell cycle regulation and protein degradation mechanisms in cancer development. His lab investigates how ubiquitin-proteasome system dysregulation—particularly involving Fbw7 tumor suppressor, cyclin E, CDK2, and Wee1 kinases—drives oncogenesis. Current work focuses on exploiting DNA replication stress and mutations in cell cycle regulators to develop targeted therapies that selectively kill cancer cells while sparing healthy tissue.

His major scientific recognitions include:

• W. M. Keck Foundation Distinguished Young Scholar (1999)
• National Cancer Institute Clinical Investigator Award
• José Carreras Fellowship
• James S. McDonnell Foundation Scholarship
• Election to American Society for Clinical Investigation (2005)

As leader of the Clurman Lab, he directs multidisciplinary research integrating biochemistry, proteomics, and genetically engineered mouse models. He actively contributes to Fred Hutch's Immunotherapy, Pathogen-Associated Malignancies, and Translational Data Science Integrated Research Centers while maintaining clinical practice in blood cancer transplantation.